Chronic lung disease
Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs in the lung. Over time these changes can cause permanent scarring in the lungs, called fibrosis, that makes it more difficult to breathe. Common symptoms are shortness of breath and coughing.
A new drug called BI1015550 has been developed to help reduce the decline in lung function and improve quality of life in people with IPF. This clinical trial evaluates whether it is safe and well tolerated by people with IPF, and tests whether it helps to reduce the impact of IPF on lung function.
What you need to know
Who can take part?
You can take part in this study if you:
- Have been diagnosed with Idiopathic Pulmonary Fibrosis by a doctor
- Are 40 years of age or older
You may not take part if you are taking immunomodulatory medications or high dose prednisone for a lung condition.
What is involved for you?
If you consent to participate in this study, you will undertake the following tests, assessments and procedures:
- Medical history and collection of demographic information
- Health questionnaires
- Physical exam
- Electrocardiogram
- Lung function tests
- Blood tests
- Pregnancy tests for women who can have children
- Take two oral tablets twice a day containing study drug or placebo for one year.
Trial dates
March 2023 to November 2023